Literature DB >> 24443366

A large case-control study reveals a positive association between bisphosphonate use and delayed dental healing and osteonecrosis of the jaw.

Gelsomina L Borromeo1, Caroline Brand, John G Clement, Michael McCullough, Lisa Crighton, Graham Hepworth, John D Wark.   

Abstract

This study sought to investigate, using a case-control study design, the association between bisphosphonate therapy and delayed dental healing and osteonecrosis of the jaw. Identification of potential cases of delayed dental healing was by consecutive screening of Specialist Oral and Maxillofacial and Special Needs Dentist clinic records for patients aged older than 50 years, during a 6-month window, in Victoria, Australia. Cases were confirmed by a case adjudication panel blinded to bisphosphonate status. Cases associated with malignancy or local radiotherapy were excluded. Controls were matched for age, sex, and source of dental referral (1:4, n = 160 controls). Variables of interest were dental precipitants, dental clinic type, smoking history, and medical comorbidities. A total of 4212 of 22,358 patients met inclusion criteria, of which 69 were potential cases with 40 (0.95%) confirmed cases. The odds ratio (OR) for developing delayed dental healing when taking an oral bisphosphonate was 13.1 (95% confidence interval [CI] 4.4 to 39.3; p < 0.001). There were no cases associated with intravenous bisphosphonate use. There was some evidence of an interaction with age, sex, and clinic type. When adjusted for smoking, the estimated odds ratio was 11.6 (95% CI 1.9 to 69.4; p = 0.01). There was an association between having another illness and delayed dental healing (OR = 2.3; 95% CI 1.0 to 5.2). A dental precipitant was present in 39 of 40 (97.5%) delayed dental healing cases. An important association between bisphosphonate use and delayed dental healing in the setting of benign bone disease, predominately in individuals with a dental precipitant, has been demonstrated.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ANTIRESORPTIVES; DENTAL BIOLOGY; OSTEOPOROSIS

Mesh:

Year:  2014        PMID: 24443366     DOI: 10.1002/jbmr.2179

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  6 in total

1.  Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells.

Authors:  Eri Katsuyama; Hiroya Miyamoto; Tami Kobayashi; Yuiko Sato; Wu Hao; Hiroya Kanagawa; Atsuhiro Fujie; Toshimi Tando; Ryuichi Watanabe; Mayu Morita; Kana Miyamoto; Yasuo Niki; Hideo Morioka; Morio Matsumoto; Yoshiaki Toyama; Takeshi Miyamoto
Journal:  J Biol Chem       Date:  2014-11-17       Impact factor: 5.157

2.  Plate Fixation for Atypical Fractures of the Femoral Diaphysis.

Authors:  Youngho Cho; Young-Soo Byun; Seongwoo Jo; Jaeuk Shin
Journal:  Clin Orthop Surg       Date:  2022-05-13

3.  Viewpoints of dentists on the use of bisphosphonates in rheumatology patients.

Authors:  Coline Daron; Christophe Deschaumes; Martin Soubrier; Sylvain Mathieu
Journal:  Int Dent J       Date:  2018-02-15       Impact factor: 2.607

Review 4.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

Review 5.  Management of atypical femoral fracture: a scoping review and comprehensive algorithm.

Authors:  Giuseppe Toro; Cristina Ojeda-Thies; Giampiero Calabrò; Gabriella Toro; Antimo Moretti; Guillermo Martínez-Díaz Guerra; Pedro Caba-Doussoux; Giovanni Iolascon
Journal:  BMC Musculoskelet Disord       Date:  2016-05-23       Impact factor: 2.362

Review 6.  Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw.

Authors:  Lina He; Xiangyu Sun; Zhijie Liu; Yanfen Qiu; Yumei Niu
Journal:  Int J Oral Sci       Date:  2020-10-21       Impact factor: 6.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.